JP2020505034A - 細胞表面コンジュゲートならびに関連する細胞組成物および方法 - Google Patents

細胞表面コンジュゲートならびに関連する細胞組成物および方法 Download PDF

Info

Publication number
JP2020505034A
JP2020505034A JP2019539186A JP2019539186A JP2020505034A JP 2020505034 A JP2020505034 A JP 2020505034A JP 2019539186 A JP2019539186 A JP 2019539186A JP 2019539186 A JP2019539186 A JP 2019539186A JP 2020505034 A JP2020505034 A JP 2020505034A
Authority
JP
Japan
Prior art keywords
cell surface
molecule
binding
cell
streptavidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019539186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505034A5 (OSRAM
Inventor
ローター ゲルメロート
ローター ゲルメロート
クリスティアン シュテムベルガー
クリスティアン シュテムベルガー
Original Assignee
ジュノ セラピューティクス ゲーエムベーハー
ジュノ セラピューティクス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジュノ セラピューティクス ゲーエムベーハー, ジュノ セラピューティクス ゲーエムベーハー filed Critical ジュノ セラピューティクス ゲーエムベーハー
Publication of JP2020505034A publication Critical patent/JP2020505034A/ja
Publication of JP2020505034A5 publication Critical patent/JP2020505034A5/ja
Priority to JP2022207775A priority Critical patent/JP2023052073A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
JP2019539186A 2017-01-20 2018-01-19 細胞表面コンジュゲートならびに関連する細胞組成物および方法 Pending JP2020505034A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022207775A JP2023052073A (ja) 2017-01-20 2022-12-26 細胞表面コンジュゲートならびに関連する細胞組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448936P 2017-01-20 2017-01-20
US62/448,936 2017-01-20
PCT/IB2018/000380 WO2018134691A2 (en) 2017-01-20 2018-01-19 Cell surface conjugates and related cell compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022207775A Division JP2023052073A (ja) 2017-01-20 2022-12-26 細胞表面コンジュゲートならびに関連する細胞組成物および方法

Publications (2)

Publication Number Publication Date
JP2020505034A true JP2020505034A (ja) 2020-02-20
JP2020505034A5 JP2020505034A5 (OSRAM) 2021-03-04

Family

ID=62555094

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019539186A Pending JP2020505034A (ja) 2017-01-20 2018-01-19 細胞表面コンジュゲートならびに関連する細胞組成物および方法
JP2022207775A Withdrawn JP2023052073A (ja) 2017-01-20 2022-12-26 細胞表面コンジュゲートならびに関連する細胞組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022207775A Withdrawn JP2023052073A (ja) 2017-01-20 2022-12-26 細胞表面コンジュゲートならびに関連する細胞組成物および方法

Country Status (9)

Country Link
US (2) US11517627B2 (OSRAM)
EP (1) EP3571221A2 (OSRAM)
JP (2) JP2020505034A (OSRAM)
CN (1) CN110418802A (OSRAM)
AU (2) AU2018209400B2 (OSRAM)
CA (1) CA3050085A1 (OSRAM)
MA (1) MA47325A (OSRAM)
MX (2) MX2019008538A (OSRAM)
WO (1) WO2018134691A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020535796A (ja) * 2017-09-06 2020-12-10 フレッド ハッチンソン キャンサー リサーチ センター ｓｔｒｅｐタグ特異的キメラ受容体およびその使用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
US20140271462A1 (en) 2013-03-13 2014-09-18 Imaginab, Inc. Antigen binding constructs to cd8
PT3083671T (pt) 2013-12-20 2020-12-24 Hutchinson Fred Cancer Res Moléculas efetoras quiméricas etiquetadas e recetores destas
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
CN115960230A (zh) 2015-08-07 2023-04-14 伊麦吉纳博公司 靶向分子的抗原结合构建体
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
CN111032850B (zh) 2017-04-27 2024-08-13 朱诺治疗学有限公司 寡聚粒子试剂及其使用方法
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
EP3847188A1 (en) * 2018-09-03 2021-07-14 Technische Universität München A double peptide tag combining reversibility and flexible functionalization
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
WO2023017115A1 (en) 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionation of cells based on a marker protein
CN113881701B (zh) * 2021-09-08 2024-04-19 山东大学 一种阳性转染细胞亲和分选方法及试剂盒
WO2025006882A1 (en) * 2023-06-30 2025-01-02 The Children's Hospital Of Philadelphia Click chemistry assisted cell surface engineering for restoring lentivirus entry

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157399A1 (en) * 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
WO2016176651A2 (en) * 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3115066A1 (en) * 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
JP2624470B2 (ja) 1984-10-02 1997-06-25 バイオジェン インコーポレイテッド ストレプトアビジン様ポリペプチドの製造
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IN165717B (OSRAM) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1990007380A2 (en) 1988-12-28 1990-07-12 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DE69128037T2 (de) 1990-11-13 1998-05-07 Immunex Corp., Seattle, Wash. Bifunktionelle wählbare fusionsgene
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
CA2211951A1 (en) 1995-02-09 1996-08-15 University Of Washington Modified-affinity streptavidin
WO1997011183A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
US6368813B1 (en) 1997-03-14 2002-04-09 The Trustees Of Boston University Multiflavor streptavidin
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
RU2149023C1 (ru) 1998-04-20 2000-05-20 Ерхов Валентин Сергеевич Способ получения специфической антисыворотки к универсальному опухолевому антигену и способ диагностики злокачественных опухолей с использованием этой антисыворотки
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
EP1520588B1 (en) 1998-07-13 2014-12-24 Board Of Regents, The University Of Texas System Uses of antibodies to aminophospholipids for cancer treatment
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
EP1178317B1 (en) 2000-07-24 2004-11-10 Health Research, Inc. Method for detection of prostate specific membrane antigen in serum
JP5312721B2 (ja) 2000-11-07 2013-10-09 シティ・オブ・ホープ Ｃｄ１９特異的再指向免疫細胞
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
US20020147312A1 (en) 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030007974A1 (en) 2001-05-30 2003-01-09 Nanus David M. Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
DE60203125T2 (de) 2001-08-31 2006-04-06 Avidex Ltd., Abingdon Löslicher t zell rezeptor
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
DE60323677D1 (de) 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2005070456A2 (en) 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
DE602005022595D1 (de) 2004-06-29 2010-09-09 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
WO2006076525A2 (en) 2005-01-14 2006-07-20 Cytogen Corporation Combination cancer therapy with anti-psma antibodies
KR20200058588A (ko) 2005-01-21 2020-05-27 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
WO2006078892A2 (en) 2005-01-21 2006-07-27 The Regents Of The University Of California Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy
WO2006110745A2 (en) 2005-04-08 2006-10-19 Cytogen Corporation Conjugated anti-psma antibodies
EP1912677B1 (en) 2005-06-20 2013-10-02 Psma Development Company, L.L.C. PSMA antibody-drug conjugates
US20070071759A1 (en) 2005-06-29 2007-03-29 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
CA2629635A1 (en) 2005-11-14 2007-05-24 Psma Development Company, Llc Compositions of and methods of using stabilized psma dimers
JP5840837B2 (ja) 2007-03-30 2016-01-06 メモリアル スローン−ケタリング キャンサー センター 養子移入ｔリンパ球における副刺激リガンドの構成性発現
US8229090B2 (en) 2007-04-17 2012-07-24 Verizon Patent And Licensing Inc. Voice portal communications
AU2015203742B2 (en) 2007-06-26 2016-12-01 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
BRPI0815848A2 (pt) * 2007-08-30 2017-06-06 The Burnet Inst composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit.
EP2433713B1 (en) 2007-12-07 2017-07-26 Miltenyi Biotec GmbH Cell processing systems and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2010135431A2 (en) 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
CA2769444A1 (en) 2009-05-19 2010-11-25 Aic Blab Company Composite current collector and methods therefor
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
HRP20190556T1 (hr) 2009-11-03 2019-06-14 City Of Hope SKRAĆENI OBLIK RECEPTORA EPIDERMALNOG FAKTORA RASTA ZA (EGFRt) ODABIR TRANSDUCIRANIH T-STANICA
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2663337A4 (en) 2011-01-10 2014-06-11 Harvard College METHOD OF DELIVERING AGENTS IN CELLS BY BACTERIAL TOXINE
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
AU2012236068A1 (en) 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN103797028B (zh) 2011-07-18 2017-08-25 Iba 股份有限公司 使靶细胞可逆染色的方法
EP2776451B1 (en) 2011-11-11 2018-07-18 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
JP6501524B2 (ja) 2012-02-24 2019-04-17 コーネル ユニヴァーシティー Ｐｓｍａ上昇により致死性前立腺癌が同定される
HK1202256A1 (en) 2012-02-28 2015-09-25 Cornell University Psma as a biomarker for androgen activity in prostate cancer
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
WO2014008155A1 (en) 2012-07-02 2014-01-09 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
KR102198058B1 (ko) 2012-10-02 2021-01-06 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
JP6340006B2 (ja) 2012-10-05 2018-06-06 コーネル ユニヴァーシティー アンドロゲン抑制、前立腺特異的膜抗原、および条件的に増大した脆弱性の概念
EP2906253B9 (en) 2012-10-12 2019-02-27 ADC Therapeutics SA Pyrrolobenzodiazepine - anti-psma antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
US10065996B2 (en) 2012-11-16 2018-09-04 Iba Gmbh Streptavidin muteins and methods of using them
ES2819573T3 (es) 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
WO2014097442A1 (ja) 2012-12-20 2014-06-26 三菱電機株式会社 車載装置及びプログラム
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN103333249A (zh) 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP2871189A1 (en) 2013-11-07 2015-05-13 Institut Pasteur High-affinity monoclonal anti-strep-tag antibody
PT3083671T (pt) 2013-12-20 2020-12-24 Hutchinson Fred Cancer Res Moléculas efetoras quiméricas etiquetadas e recetores destas
MX373458B (es) 2014-01-10 2020-05-11 Byondis Bv Metodo para purificar conjugados de anticuerpo-farmaco enlazados a cisteina.
WO2015143029A1 (en) 2014-03-18 2015-09-24 The Johns Hopkins University Psma-based molecular-genetic reporter system
CN107074929B (zh) 2014-05-02 2021-09-03 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
DK3151865T3 (da) 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
US10316093B2 (en) 2014-08-27 2019-06-11 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
MA41046A (fr) 2014-10-10 2017-08-15 Memorial Sloan Kettering Cancer Center Thérapies liées au psma
EP3256495A4 (en) 2015-02-11 2018-09-19 Aptevo Research and Development LLC Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
CN108025063A (zh) 2015-03-10 2018-05-11 索伦托治疗有限公司 结合psma的抗体治疗剂
WO2016192613A1 (zh) 2015-06-01 2016-12-08 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
CN107708741A (zh) 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
JP7074665B2 (ja) 2015-10-07 2022-05-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体に対する四価の二重特異性抗体発明の分野
CN108697096B (zh) 2016-09-02 2022-05-03 康奈尔大学 对icam-1特异性的i结构域嵌合抗原受体
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157399A1 (en) * 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
WO2016176651A2 (en) * 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3115066A1 (en) * 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
**** MATERIAL SAFETY DATA SHEET **** MSDS NAME:HUMAN HER2 / ERBB2 PROTEIN, STREP TAG, JPN6021050075, 2016, pages 1 - 3, ISSN: 0004663765 *
HUMAN HER2 /ERBB2 /CD340 PROTEIN, WITH C-TWIN STREP TAG-ACROBIOSYSTEMS, JPN6021050077, 28 February 2017 (2017-02-28), ISSN: 0004663767 *
PROTEIN SCIENCE, vol. 11, JPN6021050078, 2002, pages 883 - 893, ISSN: 0005002594 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020535796A (ja) * 2017-09-06 2020-12-10 フレッド ハッチンソン キャンサー リサーチ センター ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
JP7407701B2 (ja) 2017-09-06 2024-01-04 フレッド ハッチンソン キャンサー センター ｓｔｒｅｐタグ特異的キメラ受容体およびその使用

Also Published As

Publication number Publication date
MX2019008538A (es) 2019-11-05
AU2022218531A1 (en) 2022-11-10
WO2018134691A3 (en) 2018-11-22
US20200316218A1 (en) 2020-10-08
MA47325A (fr) 2019-11-27
JP2023052073A (ja) 2023-04-11
WO2018134691A8 (en) 2019-03-14
EP3571221A2 (en) 2019-11-27
WO2018134691A2 (en) 2018-07-26
AU2018209400A1 (en) 2019-08-01
CA3050085A1 (en) 2018-07-26
US20230190952A1 (en) 2023-06-22
AU2018209400B2 (en) 2022-06-02
MX2022015399A (es) 2023-01-16
US11517627B2 (en) 2022-12-06
CN110418802A (zh) 2019-11-05

Similar Documents

Publication Publication Date Title
US20230190952A1 (en) Cell surface conjugates and related cell compositions and methods
US20250161450A1 (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
AU2016363025B2 (en) Modified chimeric receptors and related compositions and methods
EP3664835B1 (en) Methods and compositions for preparing genetically engineered cells
JP2023062104A (ja) 免疫調節ポリペプチドならびに関連する組成物および方法
JP2023120386A (ja) Ｔ細胞療法とｂｔｋ阻害剤との併用療法
CN107206025A (zh) 用于过继细胞治疗的方法和组合物
JP2020532954A (ja) 遺伝子操作された細胞の組成物および関連組成物を産生するための方法
JP7746263B2 (ja) 細胞選択および／または細胞刺激デバイスならびに使用方法
US20250283037A1 (en) Methods for stimulating and transducing t cells
WO2023213969A1 (en) Viral-binding protein and related reagents, articles, and methods of use
RU2795454C2 (ru) Способы и композиции для получения генно-инженерных клеток
HK40096189B (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
HK40096189A (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
HK1261191A1 (en) Modified chimeric receptors and related compositions and methods
HK1261191B (en) Modified chimeric receptors and related compositions and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221226

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230106

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230111

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230303

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230308